StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Accounts Receivable by Quarter

Accounts Receivable ($M)

QuarterlyAnnual

Novartis Accounts Receivable: $9,780M in Q3 2026, up 10.6% from a year earlier. That is the highest of the 35 quarters on record here.

Latest, Q3 2026
9,780
Period ended Sep 30, 2026
Change on a year earlier
+10.6%
8,844 in Q3 2025
History
35 quarters
Since Q4 2016
Sources
34
Documents cited below

Where the Q3 2026 figure comes from

“|| Trade receivables | 9 780 | 8 937”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Postgres DB + Form 6-K.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAccounts Receivable ($M)Year on yearSource
Q3 2026Sep 30, 20269,780+10.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20269,636+6.4%Novartis 6-K (0001114448-26-000012, filed 2026-07-21) ↗
Q1 2026Mar 31, 20269,386+9.2%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20258,937+20.4%Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗
Q3 2025Sep 30, 20258,844+11.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 20259,056+10.1%Novartis 6-K (0001370368-25-000012, filed 2025-07-17) ↗
Q1 2025Mar 31, 20258,596+9.6%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 20247,423+4.4%Novartis 20-F (0001370368-25-000004, filed 2025-01-31) ↗
Q3 2024Sep 30, 20247,966+16.8%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 20248,228-10.5%Novartis 6-K (0001370368-24-000019, filed 2024-07-18) ↗
Q1 2024Mar 31, 20247,840-12.1%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 20237,107-11.9%Novartis 20-F (0001370368-24-000004, filed 2024-01-31) ↗
Q3 2023Sep 30, 20236,819-19.0%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 20239,195+6.4%Novartis 6-K (0001370368-23-000059, filed 2023-07-18) ↗
Q1 2023Mar 31, 20238,916+6.0%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 20228,066+0.8%Novartis 20-F (0001370368-23-000006, filed 2023-02-01) ↗

Cite this data

StockData. (2026). Novartis Accounts Receivable ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-bs-ar

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.